Chargement de l’entreprise
Just reported
Q3 FY2027 results
From Illumina's results release of 29 octobre 2026; its quarterly report has since been filed.
Revenue
Actual
1,13B $US
+4,2 % y/y
-2,6 % q/qGuided
—
No guide given
EPS, GAAP
Actual
1,43 $US
+46 % y/y
+5,9 % q/qGuided
—
No guide given
Operating income, GAAP
Actual
305M $US
+34 % y/y
+24 % q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Illumina is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Diagnostics and Research
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.259,4B $USA+
IDXXIdexx Laboratories Inc.55,5B $USA+
IQVIQVIA Holdings Inc.43,7B $USA
LHLabcorp Holdings Inc.30,1B $USA
DGXQuest Diagnostics Inc28,6B $USA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Comment elle gagne de l'argent
- Sequencing consumables73 %
- Services and other16 %
- Sequencing instruments11 %
Les parts du chiffre d'affaires sont des estimations pour quarter ended 2026-03-31, pas des chiffres tirés d'un document officiel.
En concurrence avec
- 300676BGI Genomics
Ce qu'elle vend6
NovaSeq X
A high-throughput DNA-sequencing machine used by customers that need to process large numbers of samples.
MiSeq i100
A lower-throughput DNA-sequencing machine for labs running smaller or more project-based batches.
NovaSeq 6000
A high-throughput DNA-sequencing machine that some customers continue to use alongside newer systems.
Afficher 3 de plus
StrataMap Spatial
A sequencing-based workflow that helps researchers study biological activity in specific locations within tissue.
SomaScan and SomaSeq
Tools for measuring proteins and connecting protein measurements with genetic information.
Billion Cell Atlas
A large collection of data on how cells respond to genetic changes, sold to drug companies for biological research and drug discovery.
Qui l'achète3
- Clinical laboratories and hospitals buy sequencing machines and supplies for testing, including cancer, inherited-disease and screening applications.
- Universities and research laboratories buy sequencing equipment and supplies to study genes, cells and biological processes.
- Drug companies buy sequencing-related services and biological data to support research and drug discovery.
Sur quoi elle repose, et ce qui pourrait la briser
Ce dont l'activité dépend
- 1Repeat consumables purchases depend on customers using Illumina machines and running samples on them.
- 2Clinical sequencing demand and purchases by large clinical customers are important sources of business growth.
- 3Instrument production depends on access to memory and other critical components, while freight costs affect expenses.
- 4Business in China is affected by restrictions associated with China's unreliable entity list.
Ce qui pourrait mal tourner
- 1If clinical laboratories expand sequencing use more slowly or run fewer samples, demand for sequencing supplies could fall.
- 2Uncertain research funding can reduce purchases by universities and research customers; research and applied consumables were declining in the quarter discussed on the call.
- 3Higher memory and freight costs, or difficulty obtaining critical components, can increase costs and disrupt instrument supply.
À propos de Illumina, Inc.
Illumina makes machines that read DNA and sells the chemicals and other supplies customers use to run samples on them. Hospitals and clinical laboratories use sequencing for applications such as cancer testing, inherited-disease testing and screening; researchers and drug companies use it to study biology and develop medicines. Illumina also sells tools for measuring proteins and provides biological data and related services.
- Siège
- San Diego, California
- Fondée en
- 1998
- Cotée sur
- Nasdaq
- Clôture de l'exercice
- Sunday nearest December 31
Construit à partir des documents déposés par Illumina, Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
